Comparison of Pregnancy Outcomes in Primigravida Receiving Low-Dose Aspirin for the Prevention of Preeclampsia.

Low-Dose Aspirin: A Game-Changer in Preventing Pre-Eclampsia and Adverse Pregnancy Outcomes in Primigravida

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07852585

Enrollment

160

Registered

2026-10-01

Start date

2025-08-01

Completion date

2026-06-30

Last updated

2026-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Brief summary

Local data on the effectiveness of low-dose aspirin in high-risk primigravida are limited. The present study was planned to compare pregnancy outcomes between high-risk primigravida receiving low-dose aspirin (75 mg/day) from 12 weeks of gestation and those not receiving aspirin.

Detailed description

Despite strong international evidence supporting low-dose aspirin for the prevention of preeclampsia, its use remains inconsistent in many developing countries, and evidence from local populations is limited. Further evaluation of its effectiveness among high-risk primigravida women may help inform appropriate clinical use and contribute to reducing adverse maternal and neonatal outcomes associated with preeclampsia.

Interventions

DRUGLow-dose aspirin

Participants received low-dose aspirin (75 mg) once daily, starting at 12 weeks of gestation and continuing until 36 weeks of gestation or delivery, along with standard care.

OTHERNo-Aspirin

Participants received standard antenatal care without aspirin.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Primigravida women * High-risk pregnancy * Aged 18-40 years * Singleton pregnancy * Gestational age ≤12 weeks

Exclusion criteria

* Women with pre-existing chronic hypertension * Renal disease * Diabetes mellitus * Autoimmune disease * Bleeding disorders * Hypersensitivity to aspirin * History of peptic ulcer disease * Those using aspirin or other antiplatelet drugs

Design outcomes

Primary

Measure	Time frame	Description
Preeclampsia	After 24 weeks of the enrollment	The frequency of patients developing preeclampsia as new-onset hypertension after 20 weeks of gestation was noted.
Placental abruption	After 24 weeks of the enrollment	The frequency of patients with placental abruption.
Preterm birth	At birth, after 24 weeks of the enrollment	The frequency of neonates born before 37 completed weeks was noted.
Low-birth-weight	At birth, after 24 weeks of the enrollment	The frequency of low-birth-weight neonates, defined as a birth weight\<2.5 kg, was noted.

Countries

Pakistan

Contacts

PRINCIPAL_INVESTIGATORShamsun Nisa, FCPS

Bahawal Victoria Hospital/Quaid-e-Azam Medical College Bahawalpur

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Oct 2, 2026